Search clinical trials for: E7449

Total 3 results

Eisai Limited

Completed

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Ovarian Cancer | Triple Negative Breast Cancer | Malignant Solid Tumour | Advanced Melanoma | B-cell Malignancy, Low-grade

United Kingdom
Allarity Therapeutics
Amarex Clinical Research; Alcedis GmbH

Active, not recruiting

Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® (PREDICT 2X-121)

Advanced Ovarian Cancer

United States, United Kingdom
The University of Texas Health Science Center at...

Withdrawn

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

Cancer of the Breast

3

Subscribe